62nd ASH Annual Meeting and Exposition: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster II

Oral and Poster Abstracts
Poster

Adult, AML, antibodies, Biological, HSCs, Leukemia, Animal models, Diseases, drug-drug interaction, Non-Biological, CAR-Ts, chemical interactions, CMML, Combinations, Elderly, Therapies, cellular interactions, checkpoint inhibitors, chemotherapy, MDS, Pediatric, Biological Processes, enzyme inhibitors, immune cells, T-Cell Lymphoma, Technology and Procedures, Cell Lineage, immunotherapy, Xenograft models, Lymphoid Malignancies, Study Population, Clinically relevant, Myeloid Malignancies, imaging, pharmacology, flow cytometry, vaccines, microenvironment, molecular interactions, RNA sequencing, proteomics

1954

Updated Analyses of a Phase 1b/2 Study of Onvansertib, a PLK1 Inhibitor, in Combination with Decitabine in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Amer M. Zeidan, MBBS, MHS¹, Tara Lin, MD², Pamela S. Becker, MD, PhD³, Gary J. Schiller, MD⁴, Prapti Patel, MD⁵, Alexander I. Spira, PhD, MD, FACP⁶^*, Michaela L. Tsai, MD⁷^*, Errin Samuëlsz⁸^*, Sandra L Silberman, MD, PhD⁹, Maya Ridinger⁸^*, Mark Erlander, PhD⁸^* and Eunice S. Wang, MD¹⁰

¹Yale University and Yale Cancer Center, New Haven, CT
²University of Kansas Medical Center, Westwood, KS
³University of Washington Inst. for Stem Cell and Regenerative Med., Seattle, WA
⁴David Geffen School of Medicine at University of California, Los Angeles, CA
⁵University of Texas Southwestern Medical Center, Dallas, TX
⁶Virginia Cancer Specialists, Fairfax, VA
⁷Minnesota Oncology, Minneapolis, MN
⁸Cardiff Oncology, San Diego, CA
⁹SLS Oncology LLC, Durham, NC
¹⁰Roswell Park Comprehensive Cancer Center, BUFFALO, NY

1955

Phase I Study of Ixazomib with Conventional Chemotherapy in the Treatment of Acute Myeloid Leukemia in Older Adults

Philip C. Amrein, MD¹, Eyal C. Attar, MD², Geoffrey Fell³^*, Traci M. Blonquist, MS³^*, Andrew M. Brunner⁴^*, Gabriela S. Hobbs, MD⁵, Hanno R. Hock, MD, PhD⁶^*, Steven L. McAfee, MD⁷^*, Rupa Narayan, MD⁵^*, Jenna A. Moran, NP⁵^*, Meghan Bergeron, NP⁵^*, Julia E. Foster, NP⁵^*, Christina Bertoli, NP⁵^*, Kristin McGregor⁵^*, Molly Macrae⁵^*, Meghan Burke⁵^*, Tanya T. Behnan, BS⁵^*, Tina T. Som, RN⁵^*, Aura Y. Ramos, RN⁵^*, Megan K. Vartanian, RN⁵^*, Jennifer Lombardi Story⁵^*, Donna S. Neuberg, ScD⁸ and Amir T. Fathi⁹

¹Leukemia Center/MGH Cancer Center, Massachusetts General Hospital, Belmont, MA
²Agios, Boston, MA
³Data Science, Dana-Farber Cancer Institute, Boston, MA
⁴Center for Leukemia, Massachusetts General Hospital, Boston, MA
⁵Leukemia Center, Massachusetts General Hospital, Boston, MA
⁶Leukemia Center, Massachusetts General Hospital / Harvard Medical School, Boston, MA
⁷Massachusetts General Hospital, Blood and Marrow Transplant Program, Boston, MA
⁸Department of Data Science, Dana-Farber Cancer Institute, Boston, MA
⁹Leukemia Center, Massachusetts General Hospital, Center for Leukemia, Cambridge, MA

1956

Therapeutic Response and Molecular Mechanisms of Novel Combination Regimen Azacitidine Plus Homoharringtonine in Acute Myeloid Leukemia with Poor Outcome

Jun Li^*, Jie Zi^*, Qi Han^*, Siyu Gu^*, Yanqing Huang^* and Zheng Ge, MD, PhD

Department of Hematology, Zhongda Hospital, Institute of Hematology Southeast University, School of Medicine, Southeast University, Nanjing, China

1957

First-in-Human Phase I Dose Escalation and Expansion Study Evaluating the Fc Optimized FLT3 Antibody Flysyn in Acute Myeloid Leukemia Patients with Minimal Residual Disease

Jonas S. Heitmann, MD¹^*, Daniela Dörfel, MD^1,2^*, Sabine Kayser, MD^3,4, Michael Heuser⁵, Felicitas Thol⁵, Silke Kapp-Schwoerer, MD⁶^*, Wolfgang Bethge, MD⁷^*, Ludger Grosse-Hovest⁸^*, Martin Steiner⁸^*, Melanie Märklin, PhD¹^*, Juliane S. Walz, MD^1,2^*, Richard F. Schlenk^9,10, Gundram Jung, MD¹¹^* and Helmut R. Salih¹²

¹Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tuebingen, Tuebingen, Germany
²Department of Hematology and Oncology, University Hospital Tuebingen, Tuebingen, Germany
³Department of Hematology, University Hospital of Leipzig, Leipzig, Germany
⁴German Cancer Research Center (DKFZ), Heidelberg, Germany
⁵Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
⁶Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany
⁷University Hospital Tübingen, Tübingen, Germany
⁸SYNIMMUNE GmbH, Tübingen, Germany
⁹Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany
¹⁰National Center of Tumor Diseases, NCT-Trial Center, German Cancer Research Center, Heidelberg, Germany
¹¹Department for Immunology, Eberhard Karls University, Tuebingen, Germany
¹²Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Partner Site Tübingen, Tuebingen, Germany

1958

Durable Remissions and Increased Overall Survival in AML Patients Deemed Unfit for Standard Intensive Chemotherapy Achieved with High-Dose BST-236 (Aspacytarabine) Induction and Consolidation

Jessica K. Altman, MD¹, Selina M. Luger, MD, FRCPC², Olga Frankfurt, MD¹^*, Tsila Zuckerman, MD³, Jamie L. Koprivnikar, MD⁴, Vamsi Kota, MD⁵, Ashkan Emadi, M.D., Ph.D.⁶, Bhavana Bhatnagar, DO⁷, Dale L. Bixby, MD⁸^*, Micah M. Burch, MD⁹, Ofir Wolach, MD¹⁰^*, Itai Levi, MD¹¹^*, Anna Gourevitch, MD¹¹^*, Ron Ram, MD¹², Liat Flaishon, PhD, MD¹³, Shoshi Tessler, PhD¹³^*, Stela Gengrinovitch, PhD¹³, Ruth Ben Yakar, PhD¹³^* and Jacob M. Rowe, MB, BS^3,14

¹Robert H. Lurie Comprehensive Cancer Center, Northwestern University, chicago, IL
²Division of Hematology/Oncology, Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA
³Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel
⁴John Theurer Cancer Center, Division of Leukemia, Hackensack Meridian Health, Hackensack Medical Center, NJ
⁵Georgia Cancer Center Augusta University, Augusta, GA
⁶Division of Hematology and Oncology, University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD
⁷Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH
⁸Comprehensive Cancer Center, University of Michigan, Grass Lake, MI
⁹Baylor Scott & White Research Institute, Dallas, TX
¹⁰Rabin Medical Center, Petah Tikva, Israel
¹¹Soroka University Medical Center, Be'er-Sheva, Israel
¹²BMT Unit, Tel Aviv (Sourasky) Medical Center and Sackler Faculty of Medicine, Tel-Aviv, Israel
¹³BioSight Ltd., Lod, Israel
¹⁴The Ruth and Bruce Rappaport Faculty of Medicine, Shaare Zedek Medical Center, Jerusalem, Israel

1959

Therapeutic Targeting of Mesothelin in Acute Myeloid Leukemia with Chimeric Antigen Receptor T Cell Therapy

Quy Le, PhD¹^*, Sommer Castro, BS¹^*, Thao T. Tang²^*, Anisha Loeb, BA¹^*, Amanda R. Leonti, MS³^*, Laura Pardo¹^*, Michael R. Loken, PhD⁴^*, Colin Correnti, PhD⁵^* and Soheil Meshinchi, MD, PhD^2,6

¹Fred Hutchinson Cancer Research Center, Seattle, WA
²Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA
³Clinical Research Division, Fred Hutchinson Cancer Research Center, Mountlake Terrace, WA
⁴Hematologics, Inc., Seattle, WA
⁵Fred Hutchinson Cancer Center, Seattle, WA
⁶Fred Hutchinson Cancer Rsrch. Ctr., Seattle, WA

1960

GRP78 Is Expressed on the Cell Surface of Pediatric AML Blasts and Can be Targeted with GRP78-CAR T Cells without Toxicity to Hematopoietic Progenitor Cells

Nikhil Hebbar, PhD¹^*, Rebecca Epperly, MD², Abishek Vaidya, MS³^*, Sujuan Huang⁴^*, Cheng Cheng, PhD⁵^*, Stephen Gottschalk, MD⁶ and Mireya Paulina Velasquez, MD⁶

¹Bone Marrow Transplantation and Cellular Therapy, St. Jude Children's Research Hospital, Memphis, TN
²Bone Marrow Transplant and Cellular Therapy, St. Jude Children's Researh Hopsital, Memphis, TN
³Bone Marrow Transplant and Cellular Therapy, St. Jude Children's Research Hospital, MEMPHIS, TN
⁴Biostatistics, St. Jude Children's Research Hospital, Memphis, TN
⁵Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, TN
⁶Department of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children's Research Hospital, Memphis, TN

1961

Venetoclax Enhances Anti-Leukemia Activity of CD123-Specific BiTE-Secreting T-Cells in AML

Hong Mu-Mosley, MD, PhD¹, Lauren B Ostermann, BS¹^*, Ran Zhao, BS¹^*, Challice L. Bonifant, MD, PhD², Stephen Gottschalk, MD³, Mireya Paulina Velasquez, MD³ and Michael Andreeff, MD, PhD¹

¹Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
²Johns Hopkins University School of Medicine, Baltimore, MD
³Department of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children's Research Hospital, Memphis, TN

1962

A Phase I/II Trial of CPX-351 + Palbociclib in Patients with Acute Myeloid Leukemia

Aziz Nazha, MD¹, Sudipto Mukherjee, MD, PhD, MPH², Caitlin Siebenaller, PharmD³^*, Madeline Waldron, PharmD, BCOP⁴^*, Eric Parsons, RN⁵^*, Jenna Thomas⁵^*, Hetty E. Carraway, MD, MBA⁶, Dale Grabowski, BS⁷^*, Yihong Guan, PhD⁷^*, Aaron T. Gerds, MD, MS⁸, Bhumika J. Patel, MD⁹, Anjali S Advani, MD¹⁰, Jaroslaw P. Maciejewski, MD, PhD¹¹ and Mikkael A. Sekeres, MD, MS¹²

¹Department of Hematology/Oncology, Cleveland Clinic, Cleveland, OH
²Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
³Department of Pharmacy, Cleveland Clinic, Cleveland, OH
⁴Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
⁵Leukemia Program, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
⁶Department of Hematology and Medical Oncology, Leukemia Program, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
⁷Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
⁸Taussig Cancer Institute, Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
⁹Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH
¹⁰Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH
¹¹Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
¹²Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

1963

Dual CXCR4 and E-Selectin Inhibition (GMI-1359) Rapidly Increases AML Cellular Motility Prior to Intravasation and Vascular Niche Depletion Observed By Intravital Bone Marrow Two-Photon Microscopy

Tomasz Zal, PhD, MSc¹, Malgorzata Anna Zal, MSc²^*, Mateusz Rytelewski, PhD³^*, Kyung Hee Chang, PhD²^*, Rodrigo Jacamo, PhD²^*, William E. Fogler, PhD⁴, John L. Magnani, PhD⁴ and Michael Andreeff, MD, PhD²

¹Section of Molecular Hematology and Therapy, Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX
²Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
³Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX
⁴GlycoMimetics, Inc., Rockville, MD

1964

Frequency and Stimulation of NPM1-Specific Immune Responses By Anti-PD1 Antibodies in NPM1-Mutated AML

Jochen Greiner, MD^1,2^*, Vanessa Schneider, Dr. rer. nat.¹^*, Hubert Schrezenmeier³, Markus Wiesneth, MD³^*, Susanne Hofmann, MD⁴^* and Marlies Götz¹^*

¹Department of Internal Medicine III, University of Ulm, Ulm, Germany
²Department of Internal Medicine, Diakonie Hospital Stuttgart, Stuttgart, Germany
³Institute for Clinical Transfusion Medicine and Immunogenetics Ulm, University of Ulm and German Red Cross, Ulm, Germany
⁴Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany

1965

ALX148 Enhances the Depth and Durability of Response to Multiple AML Therapies

Amy Chen^*, Ons Harrabi^*, Abraham P Fong, MD, PhD, Katherine L. Ruffner, MD, Alison J. Forgie, PhD^*, Janet Sim, PhD^*, Sophia S Randolph, MD, PhD, Hong Wan, PhD^*, Jaume Pons, PhD^* and Tracy C Kuo, PhD^*

ALX Oncology Inc., Burlingame, CA

1966

Biomarker Driven Umbrella Trial of Crenolanib in Combination with Ivosidenib, Enasidenib, Venetoclax, Vyxeos and/or Salvage Chemotherapy in FLT3 Mutant AML

Naval Daver, MD¹, Aaron D Goldberg, MD, PhD², Courtney D. DiNardo, MD, MSc¹, Tapan M. Kadia, MD³, Eunice S. Wang, MD⁴, Richard M. Stone, MD⁵, Han Zhang, MD, PhD⁶^* and Boo Messahel, MD⁶^*

¹Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
²Department of Medicine, Leukemia Service, Memorial Sloan-Kettering Cancer Center, New York, NY
³Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX
⁴Leukemia Service, Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY
⁵Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
⁶Arog Pharmaceuticals, Plano, TX

1967

Multi-Omic Based Antigen Discovery for the Immunotherapy of Pediatric Acute T Cell Lymphoblastic Leukemia

Nikhil Hebbar, PhD¹^*, Chunxu Qu, PhD²^*, Hong Wang, PhD³^*, Ying Shao⁴^*, Phuong Nguyen⁵^*, Abdullah Freiwan, MSc⁶^*, Rebecca Epperly, MD⁷, Yuxin Li³^*, Ji-Hoon Cho³^*, Timothy Shaw, PhD⁸^*, Junmin Peng, Ph.D.⁹^*, John Easton, PhD⁴^*, Stephen Gottschalk, MD¹⁰, Charles G Mullighan, MBBS, MD² and Mireya Paulina Velasquez, MD¹⁰

¹Bone Marrow Transplantation and Cellular Therapy, St. Jude Children's Research Hospital, Memphis, TN
²Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN
³Proteomics and Metabolomics, St. Jude Children's Research Hospital, Memphis, TN
⁴Department of Computational Biology, St. Jude Children's Research Hospital, Memphis, TN
⁵Bone Marrow Transplant and Cellular Therapy, St. Jude Children's research Hospital, Memphis, TN
⁶Bone Marrow Transplant and Cellular Therapy, St. Jude Children's Research Hospital, Memphis, TN
⁷Bone Marrow Transplant and Cellular Therapy, St. Jude Children's Researh Hopsital, Memphis, TN
⁸Computational Biology, St. Jude Children's Hospital, Memphis, TN
⁹Department of Structural Biology, St. Jude Children’s Research Hospital, Memphis, TN
¹⁰Department of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children's Research Hospital, Memphis, TN

1968

Biomarker-Driven Phase Ib Clinical Trial of OPB-111077 in Acute Myeloid Leukemia Increases Overall Response Rates

Joaquin Martinez-Lopez, MD, PhD¹^*, Pau Montesinos, MD, PhD²^*, Pilar Martinez Sanchez³^*, Julian Gorrochategui⁴^*, Jose Luis Rojas⁴^*, Daniel Primo, PhD⁴^*, Juan-Miguel Bergua, MD⁵^*, Rosa M M. Ayala, MD, PhD⁶^*, Maria Calbacho, MD⁷^*, Nieves López-Muñoz⁸^*, Evelyn Acuña, MD⁹^*, Jose Antonio Pérez-Simón, MD¹⁰^*, Adolfo de la Fuente¹¹^*, Jaime Perez De Oteyza, MD, PhD¹², Rebeca Rodríguez-Veiga, MD⁹^*, Blanca Boluda¹³^*, Isabel Cano, MD⁹^* and Joan Ballesteros, PhD¹⁴

¹Hematology Department Hospital 12 de Octubre, Complutense University, H12O-CNIO Clinical research unit, CIBERONC, Madrid, Spain
²Hematology Department, Hospital Universitario La Fe de Valencia,, Valencia, Spain, Spain
³Clinical Hematology, Hospital Universitario 12 de Octubre, Madrid, Spain
⁴Vivia Biotech, Tres Cantos, Madrid, Spain
⁵Clinical Hematology, Hospital San Pedro de Alcántara, Cáceres, Spain
⁶Hospital Universitario 12 De Octubre, Madrid, ESP
⁷Hematology and Hemotherapy, Hospital 12 de Octubre, Madrid, Spain, Spain
⁸Hematology, Hospital Universitario 12 de Octubre, Madrid, Spain
⁹Hospital Universitario y Politécnico La Fe, Valencia, Spain
¹⁰Department of Hematology, Hospital Universitario Virgen del Rocio; Instituto de Biomedicina de Sevilla (IBIS)/CSIC/Universidad de Sevilla,Spain, Sevilla, ESP
¹¹MD Anderson Cancer Center, Madrid, Spain
¹²Hospital Universitario Madrid Sanchinarro, Madrid, Spain
¹³Hospital Universitari i Politècnic La Fe, Valencia, Spain
¹⁴Vivia Biotech, Tres Cantos, MADRID, Spain

1969

Preclinical Anti-Tumor Activity of Hexabody-CD38 in Patient-Derived B Cell Lymphoma and Acute Myeloid Leukemia Xenograft Models

Ida H Hiemstra, PhD¹^*, Maarten L Janmaat, PhD²^*, Peter Boross, PhD²^*, Jeroen van den Brakel²^*, Wessel ten Hagen²^*, Sanne van Dooremalen²^*, Sieto Bosgra, PhD²^*, Bart ECG De Goeij, PhD²^*, Grietje Andringa²^*, Laurens Kil, PhD²^*, A Kate Sasser, PhD³^*, Tahamtan Ahmadi, MD, PhD⁴^*, David Satijn, PhD²^* and Esther CW Breij, PhD²^*

¹Genmab A/S, Utrecht, Netherlands
²Genmab BV, Utrecht, Netherlands
³Genmab Inc, Princeton, NJ
⁴Genmab US, Inc, Princeton, NJ

1970

Phase 1/1b Trial of Talazoparib and Gemtuzumab Ozogamicin in Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia

Amanda Przespolewski, DO¹, Elizabeth A. Griffiths, MD², James E. Thompson, MD³, Amro Elshoury, MBBChir⁴, Ashkan Emadi, M.D., Ph.D.⁵, Vu H. Duong, MD⁶, Sandrine Niyongere, MD⁷, Wendy Walinski⁸^*, Meriem Said⁹^*, Stephanie Halliwell¹⁰^*, Kemji Eke¹⁰^*, Kristopher Attwood, PhD¹¹^*, Maria R. Baer, M.D.¹² and Eunice S. Wang, MD⁴

¹Department of Medicine, Leukemia Division, Roswell Park Comprehensive Cancer Center, Buffalo, NY
²Leukemia Service, Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY
³Roswell Park Comprehensive Cancer Center, Buffalo, NY
⁴Leukemia Service, Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY
⁵University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD
⁶Division of Hematology and Oncology, University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD
⁷University of Maryland School of Medicine, Baltimore, MD
⁸Clinical Research Service, Roswell Park Comprehensive Cancer Centre, Buffalo, NY
⁹Clinical Resarch Service, Roswell Park Comprehensive Cancer Center, Buffalo, NY
¹⁰Clinical Research Service, Roswell Park Comprehensive Cancer Center, Buffalo, NY
¹¹Department of Biostatistics & Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY
¹²Greenebaum Comprehensive Cancer Center, University of Maryland, Baltimore, MD

1971

Interim Results of an Open-Label Phase IB/II Multi-Arm Study of OX40 Agonist Monoclonal Antibody (mAb), Anti-PDL1 Mab, Smoothened Inhibitor, Anti-CD33 Mab, Bcl-2 Inhibitor, and Azacitidine As Single-Agents and As Combinations for Relapsed/Refractory Acute Myeloid Leukemia

Nicholas J. Short, MD, Tapan M. Kadia, MD, Courtney D. DiNardo, MD, MSc, Naveen Pemmaraju, MD, Gautam Borthakur, MD, Guillermo Garcia-Manero, MD, Elias Jabbour, MD, Koji Sasaki, MD, Ghayas C. Issa, MD, Guillermo Montalban-Bravo, MD^*, Prithviraj Bose, MD, Jan A. Burger, MD, PhD, Darla Miller^*, Lynette Alexander-Williams^*, Farhad Ravandi, MBBS, Marina Konopleva, MD, PhD, Hagop M. Kantarjian, MD and Naval Daver, MD

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

1972

Investigation of ALLO-316: A Fratricide-Resistant Allogeneic CAR T Targeting CD70 As a Potential Therapy for the Treatment of AML

Surabhi Srinivasan, MS¹^*, Nguyen Tan¹^*, Hsin-Yuan Cheng, PhD¹^*, Yi Zhang, PhD¹^*, Silvia Tacheva-Grigorova, MS¹^*, Tom Van Blarcom¹^*, Cesar Sommer, PhD², Duy Nguyen¹^*, Barbra Sasu, PhD¹ and Siler Panowski, PhD¹

¹Allogene Therapeutics, Inc., South San Francisco, CA
²Allogene Therapeutics, Inc., San Mateo, CA

1973

Clinical Benefit and Tolerability of Crenolanib in Children with Relapsed Acute Myeloid Leukemia Harboring Treatment Resistant FLT3 ITD and Variant FLT3 TKD Mutations Treated on Compassionate Access

Katherine Tarlock, MD^1,2,3, Soheil Meshinchi, MD, PhD⁴, Jeffrey E. Rubnitz, MD⁵, Seth E. Karol, MD⁶^*, Barbara Spitzer, MD⁷, Amit J. Sabnis, MD⁸^*, Asif Pathan, PhD, RPh⁹^* and Boo Messahel, MD⁹^*

¹Division of Hematology and Oncology, Seattle Children's Hospital, Seattle, WA
²Department of Hematology & Oncology, University of Washington, Seattle, WA
³Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA
⁴Clinical Research Division, Fred Hutchinson Cancer Rsrch. Ctr., Seattle, WA
⁵Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN
⁶St. Jude Children's Research Hospital, Memphis, TN
⁷Department of Pediatrics, BMT Service, Memorial Sloan Kettering Cancer Center, New York, NY
⁸Pediatric Hematology-Oncology, UCSF Benioff Children’s Hospital San Francisco, San Francisco
⁹Arog Pharmaceuticals, Plano, TX

1974

A Phase 2 Open-Label, Multicenter, Dose Optimization Clinical Study of the Safety, Tolerability, and Pharmacokinetic (PK) and Pharmacodynamic (PD) Profiles of Cfi-400945 As a Single Agent or in Combination with Azacitidine or Decitabine in Patients with Acute Myeloid Leukemia

Brian A Jonas, MD, PhD, FACP¹, Dale L. Bixby, MD²^*, Joseph M Brandwein, MD³, Karen W.L. Yee, MD⁴, Tracy Murphy, MD, FRCP, FRCPath⁵, Mark D. Minden⁵, Glenn C. Michelson, MD⁶, Mark R Bray⁷^*, Emily Elizabeth Roberts-Thomson⁶^* and Gautam Borthakur, MD⁸

¹Department of Internal Medicine, Division of Hematology and Oncology, University of California Davis School of Medicine, Sacramento, CA
²Comprehensive Cancer Center, University of Michigan, Grass Lake, MI
³Division of Hematology, University of Alberta, Edmonton, AB, Canada
⁴Princess Margaret Cancer Center, University Health Network, Toronto, ON, Canada
⁵Leukemia Program, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
⁶Treadwell Therapeutics, Inc., Toronto, ON, Canada
⁷University Health Network, Toronto, ON, Canada
⁸Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

1975

A Novel Anti-Cancer Vaccine Approach for the Treatment of High-Risk Leukemia in Children

Thakur Satbir, PhD¹^*, Son Tran¹^*, Mohit Jain, PhD¹^*, Austin Lewis¹^*, Luis Murguia-Favela, MD¹^*, Faisal M Khan, PhD, D (ABHI)²^*, Kevin J. Bielamowicz, MD³^*, Olena Vaske, PhD⁴^*, Victor A. Lewis, MD⁵, Norman J. Lacayo, MD⁶ and Aru Narendran, MD, PhD¹^*

¹University of Calgary, Calgary, AB, Canada
²Calgary Laboratory Services, Calgary, AB, Canada
³Arkansas Children's Hospital., Little Rock, AR
⁴Department of Molecular, Cell, and Developmental Biology, University of California, Santa Cruz, Santa Cruz, CA
⁵Alberta Children's Hospital, University of Calgary, Calgary, AB, Canada
⁶Department of Pediatrics, Stanford University School of Medicine, Stanford, CA

1976

Selectivity of T Cell Engager AMV564 Against Different Leukemic Blast Populations and Potential Application for Patient Selection

Aurelien Sarde^*, Sterling Eckard, PhD^*, Li Mei^*, Curtis Ruegg, PhD^*, Patrick Chun, MD and Victoria Smith, PhD^*

Amphivena Therapeutics Inc, South San Francisco, CA

1977

Combination of Homoharringtonine with Venetoclax and Azacitidine Excerts Better Treatment Response in Relapsed /Refractory Acute Myeloid Leukemia

Guopan Yu^*, Na Xu^*, Fen Huang^*, Zhiping Fan, MD^*, Hui Liu^*, Pengcheng Shi^*, Hongsheng Zhou, MD, PhD^*, Zhixiang Wang^*, Yu Zhang^* and Qifa Liu, MD

Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH